MedTrace Logo

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

NCT04035811 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 271

Last updated 2026-04-03

No results posted yet for this study

Summary

This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants. No study medication will be administered.

Conditions

Sponsors & Collaborators

  • QED Therapeutics, a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • QED Therapeutics, Inc. VP, Clinical Development · QED Therapeutics

Eligibility

Min Age
30 Months
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-12
Primary Completion
2025-08-27
Completion
2025-08-27

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • France
  • Germany
  • Italy
  • Norway
  • Singapore
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04035811 on ClinicalTrials.gov